Nalbuphine Renaudin (Nalbuphine Hydrochloride)

The drug works as a partial agonist at μ‑opioid receptors while antagonizing κ‑opioid receptors. This dual action produces effective pain relief but limits the degree of respiratory depression, making it a useful option for acute pain management.

The appropriate dose is determined by the prescribing clinician based on the severity of pain, the patient’s medical condition, and the route of administration. Dosing guidelines are provided in the product label, and the prescriber tailors the regimen to each individual.

Safety data for Nalbuphine during pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Unlike morphine, which is a full μ‑opioid agonist, Nalbuphine is a partial agonist at μ‑receptors and an antagonist at κ‑receptors. This results in effective analgesia with a ceiling effect on respiratory depression, potentially offering a safer profile for certain patients.

Store the product at temperatures below 25 °C, in its original packaging. Protect it from moisture and direct light to maintain stability. Do not freeze the solution, and keep it out of reach of children.

Nalbuphine is supplied as a sterile injectable solution and can be given intramuscularly, intravenously, or subcutaneously. The route and rate of administration are selected by the healthcare professional according to the clinical situation and patient needs.

The most serious adverse events include respiratory depression, especially at high doses or when combined with other depressants, severe hypotension, and rare but potentially life‑threatening allergic reactions such as anaphylaxis. Prompt medical attention is required if these occur.

Patients with known hypersensitivity to nalbuphine or any component of the formulation should avoid it. It is also contraindicated in individuals with severe respiratory depression, those currently taking monoamine oxidase inhibitors, or patients for whom opioid therapy is otherwise contraindicated.